Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine (“Insilico”) will present at the 9th LSX World Congress happening in London May 3 and May 4. Zhavoronkov, an expert in generative artificial intelligence (AI) for drug discovery, will present on May 3, 2:45pm (London time) on “‘Death By Pilot’” to Asset Licensing – the Evolution of Pharma-AIDD Partnerships” as part of the Biotech Growth CEO Forum and on May 4, 9:30am (London time) on “Building a Galvanizing & Successful Transatlantic Biotech” as a Biotech Plenary.
The 9th LSX World Congress is Europe’s leading life sciences partnering and investment event, covering therapeutics, devices, digital health, deep technology, and platform technology, and showcases the deep convergence of cutting-edge research and technologies driving the healthcare industry today and in the future. The conference convenes more than 1,500 participants from around the world, including executives and commercial investors from multinational medical and pharmaceutical companies such as Merck, GSK, and Eli Lilly.
Insilico is a leading innovator in advancing new therapeutics using generative AI and reinforcement learning and has developed an end-to-end Pharma.AI platform for identifying novel targets (PandaOmics), designing new drugs (Chemistry42), and predicting the outcomes of clinical trials (InClinico). The platform has produced two drugs that have reached clinical trials. Insilico’s lead drug for the devastating chronic lung disease idiopathic pulmonary fibrosis (IPF), the first AI-discovered and AI-designed drug to advance to clinical trials, will soon be entering Phase 2 trials with patients. And the Company’s generative AI-designed drug for COVID-19 and related variants has been approved for clinical trials and has a number of design advantages over existing COVID-19 drugs.
There are 31 drugs in Insilico’s pipeline available for partnering and licensing for indications including cancer, fibrosis and immunology, and Insilico has partnered with top pharma companies like Fosun and Sanofi to advance their programs.
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases, and aging-related diseases.
For more information, visit www.insilico.com